Scarica l'app Stockscreener
1.96
5.77%
-0.12
Precedente Chiudi:
$2.08
Aprire:
$2.08
Volume 24 ore:
169.43K
Relative Volume:
0.81
Capitalizzazione di mercato:
$185.67M
Reddito:
$72.66M
Utile/perdita netta:
$34.86M
Rapporto P/E:
5.3552
EPS:
0.366
Flusso di cassa netto:
$-62.91M
1 W Prestazione:
-7.98%
1M Prestazione:
-18.67%
6M Prestazione:
-32.18%
1 anno Prestazione:
+0.51%
Intervallo 1D:
$1.93
$2.09
Intervallo di 1 settimana:
$1.93
$2.13
Portata 52W:
$1.43
$3.235
Compugen Ltd Stock (CGEN) Company Profile
Compare CGEN vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CGEN
Compugen Ltd
|
1.96 | 185.67M | 72.66M | 34.86M | -62.91M | 0.366 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-07 | Iniziato | Lake Street | Buy |
| 2026-01-07 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-13 | Iniziato | Oppenheimer | Outperform |
| 2022-08-05 | Downgrade | Jefferies | Buy → Hold |
| 2020-05-26 | Ripresa | JMP Securities | Mkt Outperform |
| 2020-05-13 | Iniziato | Stifel | Buy |
| 2020-05-07 | Iniziato | SVB Leerink | Outperform |
| 2020-04-22 | Iniziato | ROTH Capital | Buy |
| 2020-03-24 | Iniziato | SunTrust | Buy |
| 2020-01-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-03-29 | Iniziato | Oppenheimer | Outperform |
| 2016-02-01 | Ripresa | Oppenheimer | Outperform |
| 2015-10-15 | Iniziato | FBR Capital | Outperform |
| 2015-04-23 | Ripresa | Jefferies | Buy |
| 2015-04-21 | Iniziato | Oppenheimer | Outperform |
| 2014-02-07 | Iniziato | MLV & Co | Buy |
| 2009-12-28 | Reiterato | Cantor Fitzgerald | Buy |
| 2009-07-29 | Iniziato | Cantor Fitzgerald | Buy |
Mostra tutto
Compugen Ltd Borsa (CGEN) Ultime notizie
Compugen Price Target Maintained With a $4.00/Share by HC Wainwright & Co. - Moomoo
CGEN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $4.00 - GuruFocus
Stifel reiterates Compugen stock rating on ovarian trial update - Investing.com
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference - Yahoo Finance
An online conference on AI drug discovery will include Compugen. - Stock Titan
Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets - Yahoo Finance
Compugen Highlights COM701 Ovarian Trial, Expands AI Platform Into Tumor Targets - TradingView
Compugen Ltd. KOL Event (Virtual) Transcript - GuruFocus
Compugen Ltd. (CGEN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Compugen to host virtual event on COM701 ovaria... - Pluang
Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026 - Yahoo Finance
A Harvard cancer expert will discuss an ovarian cancer drug. Compugen's event is Oct. 5. - Stock Titan
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference - Eastern Progress
Compugen Shareholders Approve All Proposals at 2026 Annual Meeting - The Globe and Mail
Compugen Shareholders Approve All Proposals at 2026 Annual Meeting - TipRanks
All 2026 AGM proposals pass at Compugen (CGEN) - Stock Titan
Israel National Biotech Innovation Center Launches With Anat Cohen-Dayag as CEO of INBI Core - citybiz
Compugen to present at H.C. Wainwright Investme... - Pluang
A cancer treatment company will speak live Sept. 14. Compugen’s talk will be webcast. - Stock Titan
Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
All You Need to Know About Compugen (CGEN) Rating Upgrade to Buy - Yahoo Finance
Compugen (CGEN) Reports Q1 Loss, Lags Revenue Estimates - Eastern Progress
Compugen (CGEN) Reports Q2 Loss, Misses Revenue Estimates - Eastern Progress
Are Medical Stocks Lagging Compugen (CGEN) This Year? - Yahoo Finance
Compugen (CGEN) Earnings Brief: The Bottom-Line Figure Outpaces Its Comparison in the Latest Session; Price Reaction: Shares Finish 1.28% Up on the DayCost Structure Review - dars.gov.et
Compugen (CGEN) Earnings Brief: The Bottom-Line Figure Outpaces Its Comparison in the Latest Session; Price Reaction: Shares Finish 1.28% Up on the DayQuarterly Financial Update - dars.gov.et
Compugen (CGEN) Earnings Brief: The Bottom-Line Figure Outpaces Its Comparison in the Latest Session; Price Reaction: Shares Finish 1.28% Up on the DayEarnings Surprise Stocks - vinanet.vn
Compugen (CGEN) Dips 2.49% to $2.35, Pressure Mounts Toward Support at $2.23Price Target - vinanet.vn
Compugen (CGEN) Dips 2.49% to $2.35, Pressure Mounts Toward Support at $2.23NAAIM Leverage - dars.gov.et
Analysts Have Just Cut Their Compugen Ltd. (NASDAQ:CGEN) Revenue Estimates By 14% - simplywall.st
CGEN Q2 2026 Earnings: Loss Narrower Than Expected as EPS Surprises PositivelyMargin Expansion Trends - vinanet.vn
CGEN Q2 2026 Earnings: Loss Narrower Than Expected as EPS Surprises PositivelyMargin Expansion Trends - vinanet.vn
Compugen Ltd. (CGEN) Slides 3.6% as Biotech Stock Approaches Key $2.29 SupportBuy Signal Reports - vinanet.vn
Compugen Ltd. (CGEN) Slides 3.6% as Biotech Stock Approaches Key $2.29 SupportRelative Volume - dars.gov.et
Compugen (NASDAQ:CGEN) Share Price Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
Compugen (CGEN) Slips 1.8% to $2.46 as Shares Hover Near Key SupportSingle Stock ETF - Vinanet
Compugen (CGEN) Slips 1.8% to $2.46 as Shares Hover Near Key SupportBPI Bull Confirmed - dars.gov.et
Compugen (CGEN) Gains 4.17% to $2.50 as Immuno-Oncology Stock Shows ResilienceRVOL Breakout - dars.gov.et
Compugen (CGEN) Q2 2026 Earnings Call Transcript - AOL.com
Compugen (CGEN) Q2 2026 Earnings Call Transcript - The Globe and Mail
Compugen (CGEN) Slips 2.9% to $2.34 as Shares Approach Key Support at $2.22RVOL Spike - careplusvn.com
Compugen Ltd. (CGEN) stock price, news, quote and history - Yahoo Finance Singapore
Compugen Ltd (CGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Compugen Ltd (CGEN) Stock News Today - TradingKey
Compugen Ltd. (CGEN) Rises 2.17% to $2.35: Biotech Stock Holds Key Support as Resistance at $2.47 LoomsMFI Overbought - vinanet.vn
Compugen: Better Runway Ahead Of MAIA - Seeking Alpha
FY2026 EPS Estimates for Compugen Raised by HC Wainwright - MarketBeat
Compugen Ltd (CGEN) (Q2 2026) Earnings Call Highlights: Advancing COM701 with Strong Cash ... By GuruFocus - Investing.com Canada
Compugen Ltd (CGEN) (Q2 2026) Earnings Call Highlights: Advancin - GuruFocus
Compugen Ltd (CGEN) (Q2 2026) Earnings Call Highlights: Advancing COM701 with Strong Cash ... - Yahoo Finance
Compugen Ltd Azioni (CGEN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Compugen Ltd Azioni (CGEN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Levine Zurit | SVP, Business Development |
Jul 09 '26 |
Sale |
2.50 |
1,875 |
4,688 |
29,375 |
| Levine Zurit | SVP, Business Development |
Apr 24 '26 |
Sale |
3.20 |
2,000 |
6,400 |
29,375 |
| Ophir Eran | President and CEO |
Apr 24 '26 |
Option Exercise |
0.83 |
5,000 |
4,146 |
16,375 |
| Ophir Eran | President and CEO |
Apr 24 '26 |
Sale |
3.20 |
5,000 |
16,000 |
11,375 |
| Ophir Eran | Officer |
Apr 24 '26 |
Proposed Sale |
2.92 |
5,000 |
14,600 |
0 |
| Levine Zurit | Officer |
Apr 24 '26 |
Proposed Sale |
2.92 |
4,000 |
11,680 |
0 |
| Levine Zurit | SVP, Business Development |
Apr 24 '26 |
Option Exercise |
1.15 |
2,000 |
2,300 |
31,375 |
| Ophir Eran | President and CEO |
Apr 14 '26 |
Option Exercise |
0.83 |
5,000 |
4,146 |
16,375 |
| Ophir Eran | President and CEO |
Apr 14 '26 |
Sale |
2.90 |
5,000 |
14,521 |
11,375 |
| Levine Zurit | SVP, Business Development |
Apr 14 '26 |
Option Exercise |
1.15 |
2,000 |
2,300 |
31,375 |
4.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):